Further to earlier reports, AstraZeneca has spun off its Swedish gastrointestinal research unit into a standalone company: Albireo Pharma. AstraZeneca will own a minority stake in the new company, which is financed by Nomura Phase4 Ventures, TVM Capital and Scottish Widows Investment Partnership.
Wall Street Journal
Thursday 14 February 2008
AZ spins off GI research
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment